Introduction {#Sec1}
============

The goal of cardiopulmonary resuscitation (CPR) is to preserve the pre-arrest neurological state by maintaining sufficient cerebral blood flow and oxygenation. By generating sufficient oxygenated blood flow, ischemic brain damage is minimized \[[@CR1]\]. However, only a minority of patients following out-of hospital cardiac arrest (OHCA) experience survival without neurological injury \[[@CR2]-[@CR4]\]. Good quality bystander basic life support, shorter time between collapse and start of CPR and early defibrillation increase the chance of survival with good neurological outcome \[[@CR5]\]. Unfortunately, it is still impossible to obtain any information about organ perfusion, in particular cerebral perfusion, and ensuing ischemic organ damage during CPR. Current monitoring of the OHCA patient during CPR is limited to rhythm assessments, pulse checks between two episodes of chest compressions and end-tidal carbon dioxide \[[@CR6]\]. Currently, the latter is the only parameter proven to correlate with the likelihood of return of spontaneous circulation (ROSC), although its value for the prediction of long-term outcome has not been established and gives no particular information about the brain \[[@CR7]\].

An ideal monitor during out-of hospital CPR should be readily available for use, non-invasively, independent of a pulsatile signal and should provide information about the condition of the brain. Cerebral near-infrared spectroscopy (NIRS), a non-invasive technique, measures the regional difference between oxygenated and deoxygenated hemoglobin, an expression of the difference in oxygen supply and demand. NIRS is independent of a pulsatile signal and continuously measures cerebral oxygen saturation (rSO~2~) \[[@CR8]\]. This technique has recently been introduced in the cardiac arrest setting \[[@CR9]-[@CR17]\]. These studies suggest that rSO~2~ measured during CPR may correlate with ROSC and survival. Unfortunately, all currently available data were obtained during in-hospital CPR efforts of OHCA patients or during CPR of in-hospital cardiac arrest patients. Until now, no data are available on rSO~2~ monitoring from start of advanced life support (ALS) in patients suffering from OHCA. The purpose of this study was to measure rSO~2~ in OHCA patients from the start of ALS until ROSC or until the resuscitation efforts were terminated. We aimed to investigate whether any difference existed in the time course of rSO~2~ between patients who did or did not experience ROSC.

Methods {#Sec2}
=======

In this prospective, observational, single-center study (Ziekenhuis Oost-Limburg, Genk, Belgium) we measured pre-hospital rSO~2~ in consecutive OHCA patients. The primary aim of this study was to investigate whether there was any difference in rSO~2~ during OHCA ALS between patients who achieved ROSC and patients who do not. Furthermore, the difference in highest, lowest and initial rSO~2~ was also investigated as the proportion of time during ALS spent below 30%. The study protocol was approved by the local institutional review board (Commissie Medische Ethiek Ziekenhuis Oost-Limburg, 13--044 U). Informed consent was obtained from patient's next of kin. In circumstances in which it was not possible to obtain informed consent, the requirement for informed consent was waived, in agreement with the protocol.

An emergency vehicle, staffed by a physician trained in emergency medicine or anesthesiology and a nurse, equipped with a portable cerebral oximeter (Equanox™ 7600; Nonin Medical Inc., Plymouth, MN, USA) drove to the scene of an OHCA after an emergency call. The physician placed a single sensor on the right side of the forehead of the patient as soon as possible, in some cases immediately and in some cases after endotracheal intubation. If the sensor was applied before endotracheal intubation, 100% oxygen was delivered through a bag valve mask. All patients were intubated and ventilated with 100% oxygen. Only one rSO~2~ sensor was applied to minimize the time delay to the gold standard of care. rSO~2~ was continuously measured and registered every 4 seconds during pre-hospital ALS until CPR efforts were terminated or until the patient with ROSC arrived at the emergency department. ALS was performed following current European Resuscitation guidelines \[[@CR6]\]. In all patients, manual chest compressions were performed. None of the patients received mechanical chest compressions. If ROSC was achieved, the emergency physician pressed the event button of the cerebral oximeter and/or noted the time of ROSC on the Utstein forms \[[@CR18],[@CR19]\]. Patients were pronounced dead pre hospital or they achieved sustained ROSC (\>20 minutes) and were transported to the hospital. No patient was transported with ongoing CPR.

Exclusion criteria were age younger than 18, obvious traumatic cause of cardiac arrest and ROSC before or within 1 minute after start of rSO~2~ measurement. Emergency physicians were not blinded to rSO~2~ values because visual confirmation of the measurement and quality of the NIRS signal is necessary. However, they had not received any pre-study information regarding the interpretation of rSO~2~ values. The rSO~2~ values were therefore not used in the clinical decision-making and all patients received the best available care regardless of rSO~2~ values. The decision to stop resuscitation efforts was at the discretion of the medical emergency team. The accuracy and reliability of the used cerebral oximeter (Equanox™ 7600; Nonin Medical Inc.) has been validated against a mix of 70% jugular bulb saturation and 30% arterial saturation \[[@CR20]\].

Baseline characteristics were prospectively collected from Utstein templates and emergency medical charts \[[@CR18],[@CR19]\]. rSO~2~ data were downloaded from the portable device according to the manufacturer's instructions and exported to SPSS 20.00 (SPSS, Armonk, NY, USA) for statistical analysis. Patients were defined as achieving ROSC if ROSC was sustained for more than 20 minutes.

Because the goal of this prospective study was to investigate the rSO~2~ values in OHCA patients during ALS as a prediction for ROSC and to avoid interference from rSO~2~ measurements when ROSC was already achieved, only data obtained until 1 or 2 minutes before ROSC were used in the following data analysis. We compared initial, mean and maximum rSO~2~ values as well as the increase in rSO~2~ and the percentage of ALS time spent below a rSO~2~ value of 30%.

Statistical analysis {#Sec3}
--------------------

Patients' characteristics were compared using Student's *t* test if normally distributed or the Mann--Whitney test if not normally distributed and expressed as respectively mean ± standard deviation or median with first and third quartiles. The chi-square test and Fisher's exact test were used when comparing categorical values. Descriptive statistics were used for continuously measured rSO~2~ values and are expressed as mean ± standard deviation or median with first and third quartiles. *P* \<0.05 was considered statistically significant. All tests were performed using SPSS 20.00. Figures were made using GraphPad Prism 5.01 (GraphPad Software, La Jolla, CA, USA).

Results {#Sec4}
=======

Between December 2011 and November 2013, there were 100 eligible OHCA patients. Out of these 100 patients, rSO~2~ was measured in 56 OHCA patients (Figure [1](#Fig1){ref-type="fig"}). Data for seven patients were excluded from the analysis for the following reasons: obvious noncardiac cause of arrest (hanging) in two patients, four patients already had ROSC when rSO~2~ measurement was started, and data from one patient could not be used due to a technical defect during transfer of data. Eventually 49 patients were prospectively included, 19 (39%) patients achieved sustained ROSC whereas 30 patients (61%) did not and died pre hospital. Of the 19 patients with ROSC, 10 patients (20%) died in the emergency department and eventually three (6%) patients survived with good neurological outcome (Cerebral Performance Category 1 and 2) at hospital discharge and one patient survived with Cerebral Performance Category 4.Figure 1**Enrollment of study patients.** ROSC, return of spontaneous circulation.

Comparing ROSC with no ROSC, there were significantly more male patients in the group without ROSC (77% vs. 42%, *P* = 0.03). Age, initial rhythm, witnessed arrest, amount of epinephrine given and the number of patients in which basic life support by bystanders was started were similar in both groups (Table [1](#Tab1){ref-type="table"}). Patients with ROSC had a shorter median duration of basic life support, initiated by bystander, general practitioners or paramedics (10 (4 to 12) minutes vs. 13 (10 to 17) minutes, *P* \<0.01) and shorter median duration of ALS (16 (10 to 30) minutes vs. 25 (20 to 33) minutes, *P* = 0.02). The median time between the emergency call and the start of ALS was 14 (12 to 17) minutes in the group without ROSC and 12 (8 to 15) minutes in the group with ROSC (*P* = 0.01).Table 1**Patient demographics and characteristicsTotalNo ROSCROSC*P*** **value(** ***n***  **= 49)(** ***n***  **= 30)19)**Male31 (63)23 (77)8 (42)0.03Age73 (±17)69 (±17)70 (16)0.85First recorded rhythm Ventricular fibrillation12 (24)6 (20)6 (32)0.50 Asystole31 (63)20 (67)11 (58)0.56 Pulseless electric activity6 (15)4 (13)2 (11)1.00Bystander witnessed cardiac arrest26 (53)14 (47)12 (63)0.38EMS witnessed cardiac arrest3 (6)1 (3)2 (11)0.55Bystander CPR29 (59)20 (67)9 (47)0.24BLS duration (minutes) Total12 (9 to 16)13 (10 to 16.75)10 (4 to 12)0.01 Bystander10 (5.5 to 15)10 (7.5 to 15)5 (4 to 11.5)0.02 Paramedic6.5 (4 to 10)8 (5 to 12)4 (4 to 8.5)0.03ALS duration (minutes)21 (15.5 to 31)25 (20 to 32.75)16 (10 to 30)0.02Response time (minutes) Time (call to ALS)13 (11 to 15)14 (12 to 17.25)12 (8 to 15)0.01 Time (call to BLS)0 (0 to 4)0 (0 to 4.75)2 (0 to 4)0.48 Time (ALS to sensor placement)3 (1 to 9)5 (1.75 to 12)2 (0 to 6)0.15Epinephrine dosage (mg)5 (3 to 8)5 (4 to 8)4 (2 to 8)0.11Data are presented as number (percentage), mean (± standard deviation) or median (interquartile range). Demographic data of studied patients. ALS, advanced life support; BLS, basic life support; CPR, cardiopulmonary resuscitation; EMS, emergency medical system; ROSC, return of spontaneous circulation.

The total median increase from initial rSO~2~ values until 2 minutes before ROSC or the end of ALS efforts was significantly larger in the group with ROSC (16% (9 to 32)) compared with the patients without ROSC 10% (4 to 15) (*P* = 0.02). All results are summarized in Table [2](#Tab2){ref-type="table"}.Table 2**Cerebral saturation valuesNo ROSCROSC*P*** **value(** ***n***  **= 30)(** ***n***  **= 19)**Initial rSO~2~20 % (±13)28% (±20)0.07Initial rSO~2~, lowest value of the first minute19% (7 to 30)24% (8 to 39)0.10Initial rSO~2~, mean of the first minute27% (14 to 33)35% (8 to 43)0.11Lowest rSO~2~ value19% (7 to 3)24 %(8 to 39)0.14Highest rSO~2~ value, ROSC included40% (±16)56% (±14)\<0.01Highest rSO~2~ until 2 minutes before ROSC40% (±16)52% (±14)\<0.01Mean rSO~2~, ROSC included31% (±4)42% (±8)0.02Mean rSO~2~ until 2 minutes before ROSC31% (±4)39% (±7)0.05Increase in rSO~2~, ROSC included10% (4 to 15)18% (15 to 33)\<0.01Increase in rSO~2~ until 2 minutes before ROSC10% (4 to 15)16% (9 to 32)0.02Increase in rSO~2~ until 16 minutes11% (6 to 19) (14 pts)16% (11 to 36) (19 pts)0.05% time spent rSO~2~ ≤ 30%, ROSC included25 (0 to 100)1 (0 to 37)0.03% time spent rSO~2~ ≤ 30% until 2 minutes before ROSC25 (0 to 100)2 (0 to 36)0.05Parametric data expressed as mean (± standard deviation), nonparametric data as median (interquartile range). rSO~2~, cerebral tissue saturation; ROSC, return of spontaneous circulation.

The median duration of ALS until ROSC was 16 (10 to 30) minutes. If we compare rSO~2~ from the start of measurement until ROSC or until 16 minutes in the no ROSC group (only available in 14 patients), a significant difference in median increase is observed -- namely 11% (5.75 to 19) for the no ROSC group versus 16% (11 to 36) for the ROSC group (*P* = 0.05).

Patients who did not achieve ROSC spent a significantly higher portion of time during ALS with rSO~2~ ≤ 30% (*P* \< 0.03). The median proportion of time spent ≤30% until 2 minutes before ROSC was 25% (0 to 100) of the time for the no ROSC group compared with 2% (0 to 36) of the time for the ROSC group (*P* = 0.05). Figure [2](#Fig2){ref-type="fig"} represents the course of rSO~2~ values in both groups during ALS.Figure 2**Course of cerebral oxygen saturation during advanced life support.** Mean cerebral oxygen saturation (rSO~2~) values ± standard error of mean during advanced life support (ALS) in patients with return of spontaneous circulation (ROSC) and no ROSC.

The mean maximum rSO~2~ value until 2 minutes before ROSC recorded during ALS was significantly higher in the group that achieved ROSC (52% ± 14 vs. 40% ± 16, *P* \<0.01). The median minimal rSO~2~ value recorded during ALS, 24% (8 to 39) in the ROSC group compared with 18% (7 to 29) in the no ROSC group, did not differ (*P* = 0.14) between both groups.

There was no statistically significant difference in the mean initial recorded rSO~2~ value between the ROSC group compared with the no ROSC group (28% ± 20 vs. 20% ± 13, *P* = 0.07). The mean rSO~2~ over the first minute after the start of measurement was not different between both groups, 35% (8 to 43) in the ROSC group and 27% (14 to 33) in the no ROSC group (*P* = 0.11).

The mean rSO~2~ from the start of measurement until 2 minutes before ROSC or until ALS was terminated was higher in the ROSC group compared with the no ROSC group, respectively 39% ± 7 and 31% ± 4 (*P* = 0.05).

The mean initial rSO~2~ value of the three patients with good neurological outcome was 44% (±26). The mean rSO~2~ until 2 minutes before ROSC was 54% (±4) and the increase until 2 minutes before ROSC was 13% (±6).

Discussion {#Sec5}
==========

During pre-hospital ALS, a higher increase in rSO~2~ is observed in patients attaining ROSC, even before ROSC was clinically determined. rSO~2~ monitoring was started immediately on the arrival of the medical emergency team at the scene of cardiac arrest. During the entire course of ALS, rSO~2~ values were recorded, until ROSC or until the decision to stop ALS. Apart from three small feasibility studies, all previously published studies on this topic reported only data obtained in the emergency department, and therefore a considerable time after the cardiac arrest \[[@CR14],[@CR17],[@CR21]\]. As a result of our early pre-hospital start of rSO~2~ monitoring, it was possible to monitor patients with short ALS duration and a possibly positive neurological outcome. The time delay between start of CPR and rSO~2~ monitoring in all published studies was much longer, without information on the duration of low rSO~2~ values pre hospital and with exclusion of OHCA patients with short time to ROSC \[[@CR10]\].

As stated by others and in accordance with our results, rSO~2~ seems more useful when it is used as a dynamic information tool rather than a static one, so that a single threshold rSO~2~ value might be insufficient to predict outcome \[[@CR10],[@CR11],[@CR22]\]. However, use of the mean rSO~2~ as the threshold is not clinically useful. We used data until 2 minutes before ROSC to enable a comparison of rSO~2~ during ALS between two equivalent groups of patients: a first group who achieved ROSC and a second group in which ALS efforts were halted, but both still in cardiac arrest. We analyzed the difference in rSO~2~ increase during ALS between patients who achieved ROSC and those who did not. We found a significant difference in the increase in rSO~2~ between these groups, with an increase in rSO~2~ even before ROSC was clinically determined by means of pulse check \[[@CR23]\]. These observations support the idea for the use of cerebral saturation as a monitor during ALS. Asim and colleagues also analyzed the increase in rSO~2~ during CPR, and found a gradual increase of 5% (0 to 18) in the patients without ROSC compared with 52% (17 to 52) (*P* \<0.001) in the patients with ROSC \[[@CR16]\]. The higher increase, compared with our findings, could be due to the device used to measure rSO~2~, the Invos™ 5100C (Covidien, Boulder, CO, USA), which does not measure values below 15%. Secondly, the inclusion of rSO~2~ values at the moment of ROSC together with the rather small number of patients included (23 patients) will exacerbate differences between survivors and nonsurvivors. Thirdly, these findings are of limited added clinical value because ROSC was already determined.

In addition to the increase from start of rSO~2~ measurement until ROSC, a significant difference was also observed between the ROSC group and the no ROSC group if we compared the increase from start of ALS until 16 minutes of ALS (median duration of ALS in the ROSC group). Both findings could be a surrogate marker for better systemic oxygenation with ROSC as a result. These differences in the increase of rSO~2~ between the ROSC group and the no ROSC group suggest a high sensitivity of rSO~2~ to hemodynamic changes, which can be important during ALS for early determination of ROSC and rearrest, especially in the pre-hospital setting where monitoring modalities are limited in contrast to in-hospital cardiac arrest.

Analysis of the current results did not enable determination of a critical threshold of increase predicting ROSC with acceptable specificity/sensitivity. Probably, larger patient numbers will be needed and our ongoing multicenter trial (ClinicalTrials.gov NCT01806844) could enable us to analyze whether this critical threshold for rSO~2~ increase can be determined.

We observed no significant difference in initial rSO~2~ between patients who achieved ROSC and patients who did not achieve ROSC. The absence of a significant difference in initial rSO~2~ between the ROSC group and the no ROSC group was unexpected. We hypothesized that patients with shorter time between the emergency call and start of ALS would have a higher initial rSO~2~ value, which in turn is supported by a significantly shorter time between the emergency call and start of ALS in patients achieving ROSC. The findings therefore seem contradictory, but this could be linked to the relatively small patient population studied and the observed trend for higher initial rSO~2~ in the ROSC group. Initial rSO~2~ could be clinically interesting because it is a fast and easy observation. Although only rSO~2~ data during CPR were included, we were able to confirm the results of Parnia and colleagues that patients with ROSC had a majority of rSO~2~ values \>30% during CPR \[[@CR11]\]. Despite this confirmation, it is important to take into consideration that, amongst our group of survivors, initial rSO~2~ values of 0% were measured.

In a recent multicenter study, Ito and colleagues measured rSO~2~ in 672 OHCA patients during a 1-minute period at hospital arrival \[[@CR15]\]. A significant difference between patients with transient or sustained ROSC and no ROSC was observed. Surprisingly, only the lowest measured rSO~2~ values were used in their analysis, introducing a bias caused by suboptimal measurement. It remains unclear how the authors processed rSO~2~ values \<15% in their results because the NIRS device used does not measure below rSO~2~ of 15% (Invos™ 5100). As the study design is fundamentally different and the measuring device (NIRS) is different, comparison with our study is not possible.

This study has several limitations. Firstly, it is a small, observational, single-center study. Larger, multicenter studies are necessary to confirm current results. Secondly, the physician of the emergency medical team was not blinded to the rSO~2~ values, although there are no indications that the rSO~2~ values were used in the decision to cease or continue resuscitation efforts. Moreover, the emergency physician did not receive any information about interpretation of rSO~2~ data. Thirdly, despite the fact that we used ROSC \>20 minutes as the endpoint, only nine patients survived until arrival at the ICU and eventually only four patients survived until hospital discharge. Larger studies are necessary to compare rSO~2~ values during ALS between survivors to hospital discharge and nonsurvivors (neurological outcome). Fourthly, we could not compare our findings with end-tidal capnography, which is currently the only monitoring tool generally used during CPR, due to lack of end-tidal carbon dioxide data. Finally, none of the patients in the no ROSC group underwent an autopsy, and therefore we can only presume an arrest of cardiac origin.

Conclusion {#Sec6}
==========

We found a significant difference in increase of rSO~2~ during ALS between patients who achieved ROSC and those who did not, even before ROSC was achieved. Our findings suggest that rSO~2~ could become a surrogate marker of systemic oxygenation because a significant increase in rSO~2~ was observed before ROSC. Cerebral oximetry could have the potential to guide treatment and decision-making during cardiopulmonary resuscitation, possibly together with capnography. Currently, no initial rSO~2~ or gradient cutoff value can be defined to predict ROSC. This will remain particularly difficult as high specificity is warranted for such a cutoff value, and observed rSO~2~ values vary within a wide range. Although there is no doubt that in the clinical (pre) hospital setting a tool to quickly determine whether a patient will achieve ROSC would prove invaluable, these results are promising -- but there is still a way to go.

Key messages {#Sec7}
============

Limited information and monitoring possibilities are available during ALS in the OCHA setting.Patients who achieve ROSC have a statistically significant higher increase in cerebral saturation from start of measurement until 2 minutes before ROSC or until end of CPR efforts.Further research is necessary in larger patient groups to explore the monitoring possibilities to guide CPR efforts and to correlate cerebral saturation values with neurological outcome.
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